Osborne CK - Search Results

1

Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.

Hilsenbeck SG, Osborne CK. Hilsenbeck SG, et al. Among authors: osborne ck. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1049s-1055s. doi: 10.1158/1078-0432.CCR-05-2123. Clin Cancer Res. 2006. PMID: 16467123

2

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

Clark GM, Osborne CK, McGuire WL. Clark GM, et al. Among authors: osborne ck. J Clin Oncol. 1984 Oct;2(10):1102-9. doi: 10.1200/JCO.1984.2.10.1102. J Clin Oncol. 1984. PMID: 6491696

3

Multiple estrogen receptor assays in human breast cancer.

Hull DF 3rd, Clark GM, Osborne CK, Chamness GC, Knight WA 3rd, McGuire WL. Hull DF 3rd, et al. Among authors: osborne ck. Cancer Res. 1983 Jan;43(1):413-6. Cancer Res. 1983. PMID: 6847780

4

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

5

Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer.

Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Isola JJ, et al. Among authors: osborne ck. Am J Pathol. 1995 Oct;147(4):905-11. Am J Pathol. 1995. PMID: 7573366 Free PMC article.

6

Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.

Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Reddy KB, et al. Among authors: osborne ck. Cell Growth Differ. 1994 Dec;5(12):1275-82. Cell Growth Differ. 1994. PMID: 7696176

7

Prognostic factors: rationale and methods of analysis and integration.

Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Clark GM, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1994;32(1):105-12. doi: 10.1007/BF00666211. Breast Cancer Res Treat. 1994. PMID: 7819579 Review.

8

Heat shock proteins and drug resistance.

Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Fuqua SA, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207. Breast Cancer Res Treat. 1994. PMID: 7819588 Review.

9

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Rivkin SE, et al. Among authors: osborne ck. J Clin Oncol. 1994 Oct;12(10):2078-85. doi: 10.1200/JCO.1994.12.10.2078. J Clin Oncol. 1994. PMID: 7931477 Clinical Trial.

10

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. Osborne CK, et al. Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924. Cancer Chemother Pharmacol. 1994. PMID: 8194171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

372 results

Search Page